Canfosfamide

Summary

Canfosfamide (TLK286) is an investigational glutathione analog prodrug designed for selective activation by GST Pi-overexpressing tumor cells. It was evaluated in clinical trials for ovarian cancer, non-small cell lung cancer, and other solid tumors. Despite encouraging early results, Phase III trials did not demonstrate sufficient efficacy to support regulatory approval, and development was largely discontinued.

Mechanism of Action

Canfosfamide is a glutathione analog conjugated to a phosphorodiamide mustard alkylating agent. It is selectively activated by glutathione S-transferase Pi (GST Pi), which is overexpressed in many tumor cells, releasing an alkylating moiety that cross-links DNA and induces apoptosis in cancer cells.

Routes of Administration

Goals & Uses

• Colorectal cancer treatmentOncologyLow
• Ovarian cancer treatmentOncologyModerate
• Tumor-selective cytotoxicity via GST Pi overexpressionMechanismModerate
• Non-small cell lung cancer treatmentOncologyLow

Contraindications

• Hypersensitivity to canfosfamide or its componentsAllergyHigh
• Severe bone marrow suppressionHematologicHigh

Adverse Effects

• ThrombocytopeniaHematologicCommonLow platelet count
• AnemiaHematologicCommonLow red blood cell count or hemoglobin
• HypotensionCardiovascularUncommonLow blood pressure
• Nausea and vomitingGastrointestinalCommon
• NeutropeniaHematologicCommonLow neutrophil count
• FatigueGeneralCommonLow energy or tiredness

Drug Interactions

• Platinum-based chemotherapy (e.g., carboplatin)Moderate
• Other myelosuppressive agentsHigh

Population Constraints

• PregnancyReproductive SafetyAbsolute
• Severe renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalEvaluated in European clinical trials; no marketing authorization granted
• United StatesInvestigationalReceived Fast Track designation from FDA for ovarian cancer; Phase III trials failed; never approved
• United KingdomInvestigationalNo approval; development discontinued following negative Phase III results

Never received FDA, EMA, or other major regulatory approval. Phase III clinical trials (e.g., ASSIST-1, ASSIST-2 in ovarian cancer) did not meet primary endpoints. Development by Telik, Inc. was halted following negative trial results.

Evidence & Sources

No sources recorded yet.